Adjuvant icotinib versus observation in patients with completely resected EGFR-mutated stage IB NSCLC (GASTO1003, CORIN): a randomised, open-label, phase 2 trial

医学 危险系数 佐剂 肿瘤科 临床终点 内科学 不利影响 耐受性 肺癌 置信区间 胃肠病学 随机对照试验 外科
作者
Wei Ou,Ning Li,Bao-Xiao Wang,Tengfei Zhu,Zhilin Shen,Tao Wang,Wuguang Chang,Zeng-Hao Chang,Xinxin Hu,Yue Pu,Lieming Ding,Siyu Wang
出处
期刊:EClinicalMedicine [Elsevier BV]
卷期号:57: 101839-101839 被引量:41
标识
DOI:10.1016/j.eclinm.2023.101839
摘要

Background: This phase 2 trial aimed to compare adjuvant icotinib with observation in patients with epidermal growth factor receptor (EGFR) mutation-positive resected stage IB non-small cell lung cancer (NSCLC). Methods: We performed a randomised, open-label, phase 2 trial from May 1, 2015 to December 29, 2020 at Sun Yat-sen University Cancer Center in China. Patients with completely resected, EGFR-mutant, stage IB (the 7th edition of TNM staging) NSCLC without adjuvant chemotherapy were randomised (1:1) to receive adjuvant therapy with icotinib (125 mg, three times daily) for 12 months or to undergo observation until disease progression or intolerable toxicity occurred. The primary endpoint was 3-year disease-free survival (DFS). CORIN (GASTO1003) was registered with Clinicaltrials.gov, with the number NCT02264210. Findings: A total of 128 patients were randomised, with 63 patients in the icotinib group and 65 patients in the observation group. The median duration of follow-up was 39.9 months. The three-year DFS was significantly higher in the icotinib group (96.1%, 95% confidence interval [CI], 91.3-99.9) than in the observation group (84.0%, 95% CI, 75.1-92.9; P = 0.041). The DFS was significantly longer in the icotinib group than in the observation group, with a hazard ratio (HR) of 0.23 (95% CI, 0.07-0.81; P = 0.013). The OS data were immature, with three deaths in the observation arm. In the icotinib group, adverse events (AEs) of any grade were reported in 49 patients (77.8%), and grade 3 or greater AEs occurred in four patients (6.3%). No treatment-related deaths occurred. Interpretation: Our findings suggested that adjuvant icotinib improved the 3-year DFS in patients with completely resected EGFR-mutated stage IB NSCLC with a manageable safety profile. Funding: This study was sponsored by Betta Pharmaceutical Co., Ltd.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Eden发布了新的文献求助10
刚刚
刚刚
包容老黑完成签到,获得积分10
1秒前
1秒前
DZZH完成签到 ,获得积分10
1秒前
北岑完成签到 ,获得积分10
1秒前
1秒前
1秒前
Cipher完成签到,获得积分10
1秒前
鼓捣白发布了新的文献求助10
1秒前
singefly完成签到,获得积分20
2秒前
单薄的沛蓝完成签到,获得积分10
2秒前
缪缪拿铁完成签到,获得积分20
2秒前
zzz完成签到,获得积分10
2秒前
2秒前
NINISO完成签到,获得积分10
2秒前
wen完成签到,获得积分10
2秒前
Fan完成签到,获得积分10
2秒前
2秒前
2秒前
英吉利25发布了新的文献求助10
2秒前
小帅发布了新的文献求助10
3秒前
hehe完成签到 ,获得积分10
3秒前
dfi完成签到,获得积分10
3秒前
行走的SCI完成签到 ,获得积分10
3秒前
3秒前
4秒前
七音秦完成签到,获得积分10
4秒前
陌上发布了新的文献求助10
4秒前
huazhangchina完成签到,获得积分10
4秒前
风吹麦浪发布了新的文献求助30
4秒前
风吹麦浪发布了新的文献求助10
5秒前
风吹麦浪发布了新的文献求助30
5秒前
林林林完成签到 ,获得积分10
5秒前
风吹麦浪发布了新的文献求助10
5秒前
singefly发布了新的文献求助10
5秒前
5秒前
AAA张发布了新的文献求助10
5秒前
5秒前
luckylucky发布了新的文献求助10
5秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8174058
求助须知:如何正确求助?哪些是违规求助? 9566129
关于积分的说明 21784894
捐赠科研通 7768250
什么是DOI,文献DOI怎么找? 3431686
关于科研通互助平台的介绍 2555907
邀请新用户注册赠送积分活动 2476936